Vela José I, Crespí Jaume, Andreu David
Department of Ophthalmology, Institut Condal d'Oftalmologia, C/Aragó 469 4º 5º, 08013 Barcelona, Spain.
Int Ophthalmol. 2012 Dec;32(6):583-4. doi: 10.1007/s10792-012-9604-7. Epub 2012 Jul 5.
Ozurdex (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical removal of the implant was avoided due to the absence of anterior complications and the loss of effectiveness of the drug delivery system. Repositioning of the implant to the posterior segment is described. This case illustrates the efficacy of this technique in cases of migration into the anterior chamber in eyes without corneal decompensation.
奥助得（美国加利福尼亚州尔湾市爱力根公司）是一种可生物降解的地塞米松植入物（0.7毫克），注入玻璃体腔用于治疗黄斑水肿。我们报告了一例曾植入虹膜爪状晶状体的患者，奥助得迁移至前房的病例。由于无前部并发症且药物递送系统失效，未进行植入物的手术取出。描述了将植入物重新定位至眼后段的方法。该病例说明了该技术在无角膜失代偿的眼中植入物迁移至前房的情况下的有效性。
